Nanobiotix (NASDAQ:NBTX) Sees Unusually-High Trading Volume – Should You Buy?

Shares of Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) saw strong trading volume on Wednesday. 90,160 shares were traded during trading, an increase of 1% from the previous session’s volume of 88,938 shares. The stock last traded at $32.0210 and had previously closed at $31.50.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on NBTX. Leerink Partners boosted their price target on shares of Nanobiotix from $37.00 to $46.00 and gave the stock an “outperform” rating in a research report on Thursday, June 4th. Guggenheim assumed coverage on shares of Nanobiotix in a research report on Tuesday, September 15th. They set a “buy” rating and a $64.00 price objective for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Nanobiotix in a research note on Friday, July 17th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $46.67.

Nanobiotix Stock Performance

The business has a 50-day simple moving average of $38.51 and a 200-day simple moving average of $37.29.

About Nanobiotix

Nanobiotix is a clinical-stage biotechnology company focused on developing nanomedicine-based therapies for cancer. The company’s technology is designed to improve the effectiveness of radiotherapy by using nanoparticles that interact with radiation inside tumors, with the goal of enhancing tumor-cell destruction while limiting damage to surrounding healthy tissue.

Its lead product candidate, NBTXR3, is an investigational radioenhancer consisting of functionalized hafnium oxide nanoparticles.